Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients

American Journal of Gastroenterology

Volumn 102, Issue 2, 2007, Pages 331-337

  Matsuoka, Katsuyoshi ^a   Iwao, Yasushi ^b   Mori, Takeshi ^a   Sakuraba, Atsushi ^a   Yajima, Tomoharu ^a   Hisamatsu, Tadakazu ^a   Okamoto, Susumu ^a   Morohoshi, Yuichi ^a   Izumiya, Motoko ^a   Ichikawa, Hitoshi ^a   Sato, Toshiro ^a   Inoue, Nagamu ^b   Ogata, Haruhiko ^a   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY   (Japan)

^b KEIO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIBODY; EOSIN; GANCICLOVIR; HEMATOXYLIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MESALAZINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TACROLIMUS; VIRUS ANTIGEN;

ADOLESCENT; ADULT; AGED; APHERESIS; ARTICLE; COLON RESECTION; CONTROLLED STUDY; CYTAPHERESIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIGENS, VIRAL; BIOPSY; COLITIS, ULCERATIVE; COLON; CYCLOSPORINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 33846508534     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00989.x     Document Type: Article

References (26)

1. Goodgame RW. Gastrointestinal cytomegalovirus disease. Ann Intern Med 1993;119:924-35.
2. Berk T, Gordon SJ, Choi HY, et al. Cytomegalovirus infection of the colon: A possible role in exacerbations of inflammatory bowel disease. Am J Gastroenterol 1985;80:355-60.
3. Orloff JJ, Saito R, Lasky S, et al. Toxic megacolon in cytomegalovirus colitis. Am J Gastroenterol 1989;84:794-7.
4. Loftus EV Jr, Alexander GL, Carpenter HA. Cytomegalovirus as an exacerbating factor in ulcerative colitis. J Clin Gastroenterol 1994;19:306-9.
5. Vega R, Bertran X, Menacho M, et al. Cytomegalovirus infection in patients with inflammatory bowel disease. Am J Gastroenterol 1999;94:1053-6.
6. Cottone M, Pietrosi G, Martorana G, et al. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol 2001;96:773-5.
7. Papadakis KA, Tung JK, Binder SW, et al. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol 2001;96:2137-42.
8. Streetz KL, Buhr T, Wedemeyer H, et al. Acute CMV-colitis in a patient with a history of ulcerative colitis. Scand J Gastroenterol 2003;38:119-22.
9. Kambham N, Vij R, Cartwright CA, et al. Cytomegalovirus infection in steroid-refractory ulcerative colitis: A case-control study. Am J Surg Pathol 2004;28:365-73.
10. Gondo H, Minematsu T, Harada M, et al. Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation. Br J Haematol 1994;86:130-7.
11. Mori T, Mori S, Kanda Y, et al. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2004;33:431-4.
12. Mori T, Okamoto S, Matsuoka S, et al. Risk-adapted preemptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 2000;25:765-9.
13. Kanda Y, Mineishi S, Saito T, et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplant 2001;27:437-44.
14. de Saussure P, Lavergne-Slove A, Mazeron MC, et al. A prospective assessment of cytomegalovirus infection in active inflammatory bowel disease. Aliment Pharmacol Ther 2004;20:1323-7.
15. Wada Y, Matsui T, Matake H, et al. Intractable ulcerative colitis caused by cytomegalovirus infection: A prospective study on prevalence, diagnosis, and treatment. Dis Colon Rectum 2003;46:S59-65.
16. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:2-6; discussion 16-9.
17. Gower-Rousseau C, Salomez JL, Dupas JL, et al. Incidence of inflammatory bowel disease in northern France (1988-1990). Gut 1994;35:1433-8.
18. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. BMJ 1955;2:1041-8.
19. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
20. Naganuma M, Funakoshi S, Sakuraba A, et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 2004;10:251-7.
21. Sawada K, Kusugami K, Suzuki Y, et al. Leukocytapheresis in ulcerative colitis: Results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 2005;100:1362-9.
22. Mori T, Okamoto S, Watanabe R, et al. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;29:777-82.
23. Bernabeu-Wittel M, Pachon-Ibanez J, Cisneros JM, et al. Quantitative pp65 antigenemia in the diagnosis of cytomegalovirus disease: Prospective assessment in a cohort of solid organ transplant recipients. J Infect 2005;51:188-94.
24. Takahashi Y, Tange T. Prevalence of cytomegalovirus infection in inflammatory bowel disease patients. Dis Colon Rectum 2004;47:722-6.
25. Van Den Berg AP, Klompmaker IJ, Haagsma EB, et al. Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. J Infect Dis 1991;164:265-70.
26. Simon CO, Seckert CK, Dreis D, et al. Role for tumor necrosis factor alpha in murine cytomegalovirus transcriptional reactivation in latently infected lungs. J Virol 2005;79:326-40.